|本期目录/Table of Contents|

[1]阮越勇,王蓓蕾,李想,等.慢性阻塞性肺疾病稳定期中医证候与理化检测指标的相关性研究[J].环球中医药,2017,10(04):401-405.[doi:10.3969/j.issn.1674-1749.2017.04.005]
　RUAN Yueyong,WANG Beilei,LI Xiang,et al.Relevant research of TCM syndrome and physical and chemical detection index of stable COPD[J].,2017,10(04):401-405.[doi:10.3969/j.issn.1674-1749.2017.04.005]
点击复制

慢性阻塞性肺疾病稳定期中医证候与理化检测指标的相关性研究()
     
分享到：

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第10卷
期数:
2017年04期
页码:
401-405
栏目:
COPD研究专题
出版日期:
2017-04-06

文章信息/Info

Title:
Relevant research of TCM syndrome and physical and chemical detection index of stable COPD
作者:
阮越勇; 王蓓蕾; 李想; 张纾难
100029 北京中医药大学研究生院[阮越勇(博士研究生)、王蓓蕾(硕士研究生)、李想(硕士研究生)]; 国家呼吸疾病临床研究中心 中日友好医院呼吸中心 中日友好医院中医肺病科[阮越勇(博士研究生)、王蓓蕾(硕士研究生)、李想(硕士研究生)、张纾难]
Author(s):
RUAN Yueyong; WANG Beilei; LI Xiang; et al.
China-Japan friendship hospital pulmonary disease of traditional Chinese medicine, Beijing 100029, China
关键词:
慢性阻塞性肺疾病;  相关检测;  中医证候;  关联性;  血常规;  血脂;  肺功能
Keywords:
Chronic obstructive pulmonary disease;  Correlation detection;  TCM syndrome;  Correlation;  Routine blood;  Blood lipid;  Lung function
分类号:
R259
DOI:
10.3969/j.issn.1674-1749.2017.04.005
文献标志码:
A
摘要:
目的 探讨5个慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期常见的证候(肺气虚、肺肾气虚、肺脾气虚、痰湿蕴肺、痰瘀阻肺)与相关检测指标的关系。方法 在中日友好医院中医肺病科和呼吸科门诊和病房经过筛选共收69例符合条件的COPD患者,将患者分为5组(肺气虚组、肺肾气虚组、肺脾气虚组、痰湿蕴肺组、痰瘀阻肺组)采用呼吸困难分级评分(modified british medical research Council,mMRC)调查表和COPD患者生活质量评估问卷(COPD assessment test,CAT)对患者健康状况调查,血常规、血生化、血气分析、肺功能,将5组的资料进行统计学分析。结果(1)痰湿蕴肺组患者白细胞比痰瘀阻肺组、肺气虚组、肺脾气虚组、肺肾气虚组高,经统计学分析结果均有差异(P＜0.05); 痰湿蕴肺组患者中性粒细胞百分率比肺脾气虚组高,经统计学分析结果均有差异(P＜0.05)。(2)肺肾气虚组的总胆固醇(total cholesterol,TC)比肺气虚组、肺脾气虚组、痰湿蕴肺组高,差异有统计学意义(P＜0.05); 痰瘀阻肺组的总胆固醇比肺气虚组、肺脾气虚组、痰湿蕴肺组高,经统计学分析结果有差异(P＜0.05); 痰瘀阻肺组的低密度脂蛋白(low density lipoprotein,LDL)比肺气虚组、肺肾气虚组、肺脾气虚组、痰湿蕴肺组高,经统计学分析结果均有差异(P＜0.05)。(3)肺肾气虚组患者的用力肺活量(forced vital capacity,FVC)和一秒用力呼气容积(forced expiratory volume in one second,FEV1)比肺气虚组、肺脾气虚组、痰湿蕴肺组低,差异有统计学意义(P＜0.05); 痰瘀阻肺组患者肺功能FVC、FEV1比肺气虚组、肺脾气虚组低,经统计学分析结果有差异(P＜0.05); 痰湿蕴肺组的肺功能FEV1比肺气虚组低,经统计学分析结果均有差异(P＜0.05); 肺肾气虚组的肺功能FEV1/FVC比肺气虚组、肺脾气虚组低,经统计学分析结果均有差异(P＜0.05)。(4)肺肾气虚组的血氧分压比肺气虚组、肺脾气虚组、痰湿蕴肺组、痰瘀阻肺组低,经统计学分析结果有差异(P＜0.05)。肺肾气虚组的血二氧化碳分压比肺气虚组、肺脾气虚组、痰湿蕴肺组,痰瘀阻肺组高,经统计学分析结果均有差异(P＜0.05)。(5)痰瘀阻肺组的mMRC比肺气虚组、肺脾气虚组、痰湿蕴肺组高; 肺肾气虚组的mMRC比肺气虚组高,经统计学分析结果均有差异(P＜0.05)。肺气虚组的CAT比肺肾气虚组、痰瘀阻肺组、痰湿蕴肺组低,经统计学分析结果有差异(P＜0.05)。结论 研究说明随着COPD患者病情的进展和复杂化,中医证候的理化检测指标亦可出现不同程度的变化。
Abstract:
Objective To study the relationship of common syndromes(Feiqixu, Feishenqixu, Feipiqixu, Tanshiyunfei, Tanyuzufei)of chronic obstructive pulmonary disease(COPD)in stable phase with the related indicators. Methods 69 cases of eligible patients with COPD in pneumology department and lung disease of China-Japan friendship hospital were filtered, the patients were divided into 5 groups(Feiqixu group, Feishenqixu group, Feipiqixu group, Tanshiyunfei group, Tanyuzufei group), breathing difficulties classification score(mMRC)questionnaire and COPD patients quality of life assessment questionnaire(CAT)was used to investigate patients' health, blood routine, blood biochemistry, blood gas analysis, pulmonary function. The data of 5 groups were analysed statistically. Results(1)WBC of Tanshiyunfei group was higher than Tanyuzufei group, Feiqixu group, Feipiqixu group and Feishenqixu group, results had significant difference(P＜0.05). NEUT% of Tanshiyunfei group was higher than Feipiqixu group, results have significant difference(P＜0.05).(2)Total cholesterol of Feishenqixu group was higher than Feiqixu group, Feipiqixu group and Tanshiyunfei group. total cholesterol of Tanyuzufei group was higher than Feiqixu group, Feipiqixu group and Tanshiyunfei group, results had significant difference(P＜0.05). LDL-C of Tanyuzufei group blood was higher than Feiqixu group, Feishenqixu group and Feipiqixu group, results had significant difference(P＜0.05).(3)Forced vital capacity and forced expiratory volume in one second of Feishenqixu group was lower than Feiqixu group, Feipiqixu group, Tanshiyunfei group is low and Tanyuzufei group, results had significant difference(P＜0.05). FVC and FEV1 of Feishenqixu group was lower than Feiqixu group, Feipiqixu group and Tanshiyunfei group; FEV1 of Tanyuzufei group was lower than Feiqixu group,results had significant difference(P＜0.05). FEV1 / FVC of Feishenqixu group was lower than Feiqixu group and Feipiqixu group, results had significant difference(P＜0.05).(4)Blood PaO2 of Feishenqixu group was higher than Feiqixu group, Feipiqixu group, Tanshiyunfei group and Tanyuzufei group, results had significant difference(P＜0.05). PaCO2 of Feishenqixu group was higher than Feiqixu group, Feipiqixu group, Tanshiyunfei group and Tanyuzufei group, results had significant difference(P＜0.05).(5)mMRC of Tanyuzufei group was higher than Feiqixu group, Feipiqixu group and Tanshiyunfei group. mMRC of Feishenqixu group was higer than Feiqixu group, results had significant differences(P＜0.05). CAT of Feiqixu group was lower than Feishenqixu group, Tanyuzufei group and Tanshiyunfei group, the results had significant difference(P＜0.05). Conclusion The results show that the physical and chemical indexes of TCM syndrome can be changed to varying degrees with the development and complication of COPD.

参考文献/References:

[1] 中华医学会.临床诊疗指南呼吸病学分册[M].北京:人民卫生出版社,2014:11.
[2] 姚婉贞,徐永健.慢性阻塞性肺疾病[M].北京:北京大学医学出版社,2007:312-313.
[3] 王永炎,严世芸.实用中医内科学[M].上海:上海科学技术出版社,2009:164-165.
[4] 周仲英,蔡淦.中医内科学[M].北京:人民卫生出版社,2014:145-157.
[5] 钟南山,刘又宁.呼吸病学[M].北京:人民卫生出版社,2012:543-552.
[6] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:1-5.
[7] 中华中医药学会.中医内科常见病诊疗指南西医疾病部分[M].北京:中国中医药出版社,2008:71-73.
[8] 蔡映云.慢性阻塞性肺疾病[M].北京:科学出版社,2010:51-60.
[9] 苏铭瑞,张纾难.补肺益肾法对慢性阻塞性肺疾病稳定期患者的疗效及生活质量影响的临床研究[J].中华中医药学刊,2015,33(8):1837-1840.

相似文献/References:

[1]杨云霜 张蓉 杨金亮 李延晖 邹梦颖.慢性阻塞性肺疾病季节性发病中医机理 探讨[J].环球中医药,2013,6(05):342.
[2]乐一萍,孙燕妮.中医防治慢性阻塞性肺疾病的机制研究进展[J].环球中医药,2013,6(03):226.
　LE Yi ping,SUN Yan ni..The progress of Chinese medicine for prevention and treatment of chronic obstructive pulmonary disease mechanisms[J].,2013,6(04):226.
[3]李京,伍燕兵,曹志新,等.健脾益肺汤治疗肺脾气虚型慢性阻塞性肺疾病无创机械通气患者临床研究[J].环球中医药,2013,6(10):725.
　LI Jing,WU Yan bing,CAO Zhi xin,et al.Clinical research of Jianpi Yifei Decoction on treating COPD patients of lungspleen qi deficiency who need noninvasive mechanical ventilation[J].,2013,6(04):725.
[4]曹芳,吴志松,王玮,等.周平安教授诊治慢性阻塞性肺疾病经验[J].环球中医药,2015,8(12):1496.[doi:10.3969/j.issn.1674.1749.2015.12.023]
[5]王玮 王琦 吴海斌 张永生 焦扬.COPD肺络微型癥瘕的分子病理学阐释[J].环球中医药,2016,9(08):946.[doi:10.3969/j.issn.1674-1749.2016.08.011]
　Wang Wei,Wang Qi,WU Hai-bin,et al.The explanation of molecular pathology of micro-zhengjia in feiluo with COPD[J].,2016,9(04):946.[doi:10.3969/j.issn.1674-1749.2016.08.011]
[6]滑宬 何明.从虚、痰、气、瘀论治慢性阻塞性肺病经验[J].环球中医药,2017,10(07):753.[doi:10.3969/j.issn.1674-1749.2017.07.023]
[7]薛柏华,张伟,董洪珍.慢性阻塞性肺疾病合并营养不良的中医证型及治疗的相关研究进展[J].环球中医药,2017,10(10):1178.[doi:10.3969/j.issn.1674-1749.2017.10.038]
　XUE Baihua,ZHANG Wei,DONG Hongzhen..Research progress of TCM syndromes and treatment of chronic obstructive pulmonary disease combined with malnutrition[J].,2017,10(04):1178.[doi:10.3969/j.issn.1674-1749.2017.10.038]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金(81541173); 国家临床重点专科
作者简介: 阮越勇(NGUYEN VIET DUNG)(1988- ),越南籍,2016级在读博士研究生。研究方向:中医药防治呼吸系统疾病。E-mail:vietdzung24@yahoo.com
通信作者:张纾难(1963- ),博士,主任医师,教授,博士生导师。研究方向:中医药防治呼吸系统疾病。E-mail:shunan_zhang2010@qq.com
更新日期/Last Update: 2017-04-06